Health equity innovation in precision medicine: data stewardship and agency to expand representation in clinicogenomics

Most forms of clinical research examine a very minute cross section of the patient journey. Much of the knowledge and evidence base driving current genomic medicine practice entails blind spots arising from underrepresentation and lack of research participation in clinicogenomic databases. The flaws are perpetuated in AI models and clinical practice guidelines that reflect the lack of diversity in data being used. Participation in clinical research and biobanks is impeded in many populations due to a variety of factors that include knowledge, trust, healthcare access, administrative barriers, and technology gaps. A recent symposium brought industry, clinical, and research participants in clinicogenomics to discuss practical challenges and potential for new data sharing models that are patient centric and federated in nature and can address health disparities that might be perpetuated by lack of diversity in clinicogenomic research, biobanks, and datasets. Clinical data governance was recognized as a multiagent problem, and governance practices need to be more patient centric to address most barriers. Digital tools that preserve privacy, document provenance, and enable the management of data as intellectual property have great promise. Policy updates realigning and rationalizing clinical data governance practices are warranted.

Authors

Institutions

Publication Details

Journal
Health Research Policy and Systems
Published
2024-12-18
DOI
https://doi.org/10.1186/s12961-024-01258-9
Citations
5
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
1.43

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Health equity innovation in precision medicine: data stewardship and agency to expand representation in clinicogenomics

Marcia G. Ory, Reid T. Powell, Jochen Hinkel, Kenneth S. Ramos et al.
5 citations
Health Research Policy and Systems
Cancer Genomics and Diagnostics
1.43
article

Health equity innovation in precision medicine: data stewardship and agency to expand representation in clinicogenomics

Marcia G. Ory, Reid T. Powell, Jochen Hinkel, Kenneth S. Ramos, Adam Hansen, Patrick Silva, Vasiliki Rahimzadeh, Scott L. Grossman, Junaid Husain, Rafael Rosengarten
article en
5 citations

Abstract

Most forms of clinical research examine a very minute cross section of the patient journey. Much of the knowledge and evidence base driving current genomic medicine practice entails blind spots arising from underrepresentation and lack of research participation in clinicogenomic databases. The flaws are perpetuated in AI models and clinical practice guidelines that reflect the lack of diversity in data being used. Participation in clinical research and biobanks is impeded in many populations due to a variety of factors that include knowledge, trust, healthcare access, administrative barriers, and technology gaps. A recent symposium brought industry, clinical, and research participants in clinicogenomics to discuss practical challenges and potential for new data sharing models that are patient centric and federated in nature and can address health disparities that might be perpetuated by lack of diversity in clinicogenomic research, biobanks, and datasets. Clinical data governance was recognized as a multiagent problem, and governance practices need to be more patient centric to address most barriers. Digital tools that preserve privacy, document provenance, and enable the management of data as intellectual property have great promise. Policy updates realigning and rationalizing clinical data governance practices are warranted.

Health Research Policy and SystemsVol. 22(1)
Texas A&M Health Science Center (US), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Intel (United States) (US), Texas A&M University System (US), Baylor College of Medicine (US), Texas A&M Health Science Center (US), Texas A&M University (US)
Genentech Foundation, Gulf Coast Consortium for Innovative Drug Discovery and Development, Genentech
Industry, innovation and infrastructure
Openalex Percentile: Top 17%
Cancer Genomics and Diagnostics
1.43
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.